281 related articles for article (PubMed ID: 24885513)
1. A novel approach to identify driver genes involved in androgen-independent prostate cancer.
Schinke EN; Bii V; Nalla A; Rae DT; Tedrick L; Meadows GG; Trobridge GD
Mol Cancer; 2014 May; 13():120. PubMed ID: 24885513
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.
Nalla AK; Williams TF; Collins CP; Rae DT; Trobridge GD
Mol Carcinog; 2016 Nov; 55(11):1761-1771. PubMed ID: 26512949
[TBL] [Abstract][Full Text] [Related]
3. Mutagenesis Screens for Prostate Cancer Using Replication-Incompetent Lentiviral Vectors.
Trobridge GD
Methods Mol Biol; 2019; 1907():103-114. PubMed ID: 30542994
[TBL] [Abstract][Full Text] [Related]
4. Replication-incompetent gammaretroviral and lentiviral vector-based insertional mutagenesis screens identify prostate cancer progression genes.
Bii VM; Collins CP; Hocum JD; Trobridge GD
Oncotarget; 2018 Mar; 9(21):15451-15463. PubMed ID: 29643985
[TBL] [Abstract][Full Text] [Related]
5. A novel gammaretroviral shuttle vector insertional mutagenesis screen identifies SHARPIN as a breast cancer metastasis gene and prognostic biomarker.
Bii VM; Rae DT; Trobridge GD
Oncotarget; 2015 Nov; 6(37):39507-20. PubMed ID: 26506596
[TBL] [Abstract][Full Text] [Related]
6. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.
Whitworth H; Bhadel S; Ivey M; Conaway M; Spencer A; Hernan R; Holemon H; Gioeli D
PLoS One; 2012; 7(6):e38950. PubMed ID: 22761715
[TBL] [Abstract][Full Text] [Related]
7. Identifying Cancer Driver Genes Using Replication-Incompetent Retroviral Vectors.
Bii VM; Trobridge GD
Cancers (Basel); 2016 Oct; 8(11):. PubMed ID: 27792127
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis.
Wang Z; Wang Z; Guo J; Li Y; Bavarva JH; Qian C; Brahimi-Horn MC; Tan D; Liu W
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3053-8. PubMed ID: 22315407
[TBL] [Abstract][Full Text] [Related]
10. A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.
Speransky S; Serafini P; Caroli J; Bicciato S; Lippman ME; Bishopric NH
Breast Cancer Res Treat; 2019 Jul; 176(2):271-289. PubMed ID: 31006104
[TBL] [Abstract][Full Text] [Related]
11. Stabilization of ADAM9 by N-α-acetyltransferase 10 protein contributes to promoting progression of androgen-independent prostate cancer.
Lin YW; Wen YC; Chu CY; Tung MC; Yang YC; Hua KT; Pan KF; Hsiao M; Lee WJ; Chien MH
Cell Death Dis; 2020 Jul; 11(7):591. PubMed ID: 32719332
[TBL] [Abstract][Full Text] [Related]
12. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
13. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC
Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825
[TBL] [Abstract][Full Text] [Related]
14. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
[TBL] [Abstract][Full Text] [Related]
15. Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.
Wang T; Abou-Ouf H; Hegazy SA; Alshalalfa M; Stoletov K; Lewis J; Donnelly B; Bismar TA
J Mol Med (Berl); 2016 Dec; 94(12):1411-1422. PubMed ID: 27534968
[TBL] [Abstract][Full Text] [Related]
16. MEX3D is an oncogenic driver in prostate cancer.
Shao L; Wang J; Karatas O; Ittmann M
Prostate; 2021 Nov; 81(15):1202-1213. PubMed ID: 34455614
[TBL] [Abstract][Full Text] [Related]
17. Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.
D'Antonio JM; Vander Griend DJ; Antony L; Ndikuyeze G; Dalrymple SL; Koochekpour S; Isaacs JT
PLoS One; 2010 Jul; 5(7):e11475. PubMed ID: 20628607
[TBL] [Abstract][Full Text] [Related]
18. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
19. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
[TBL] [Abstract][Full Text] [Related]
20. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
